For research use only, not for therapeutic use.
Briciclib (Cat No.:I004988) is a small-molecule inhibitor that disrupts the expression of cyclin D1, a protein crucial for cell cycle progression and cancer cell proliferation. By targeting cyclin D1 mRNA translation, Briciclib reduces its levels, leading to cell cycle arrest and apoptosis in cancer cells, particularly those reliant on overexpressed cyclin D1. This compound has shown potential in treating various cancers, including multiple myeloma and breast cancer. Briciclib’s ability to selectively target cancer cells makes it a promising candidate for further development in cancer therapeutics, particularly in combination regimens.
| Catalog Number | I004988 |
| CAS Number | 865783-99-9 (free acid) |
| Synonyms | ON013105; ON-013105; ON 013105; ON 014185; ON014185; ON-014185; ON-013105 sodium, Briciclib.;(E)-2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl dihydrogen phosphate |
| Molecular Formula | C19H23O10PS |
| Purity | ≥95% |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4°C for short term ,or -20 °C for long term |
| InChI | InChI=1S/C19H23O10PS/c1-25-14-10-17(27-3)15(18(11-14)28-4)7-8-31(23,24)12-13-5-6-16(26-2)19(9-13)29-30(20,21)22/h5-11H,12H2,1-4H3,(H2,20,21,22)/b8-7+ |
| InChIKey | LXENKEWVEVKKGV-BQYQJAHWSA-N |
| SMILES | O=P(O)(O)OC1=CC(CS(=O)(/C=C/C2=C(OC)C=C(OC)C=C2OC)=O)=CC=C1OC |
| Reference | </br>1. Prasad A, Shrivastava A, Papadopoulos E, Kuzontkoski PM, Reddy MV, Gillum AM, Kumar R, Reddy EP, Groopman JE. Combined administration of rituximab and on 013105 induces apoptosis in mantle cell lymphoma cells and reduces tumor burden in a mouse model of mantle cell lymphoma. </br>Clin Cancer Res. 2013 Jan 1;19(1):85-95. doi: 10.1158/1078-0432.CCR-12-1425. Epub 2012 Nov 1. PubMed PMID: 23124440. |
